Griseofulvin Ultramicrosize Tablets and Orfadin (Nitisinone Oral Suspension)
Determining the interaction of Griseofulvin Ultramicrosize Tablets and Orfadin (Nitisinone Oral Suspension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme. However, data evaluating the interaction are not available. MANAGEMENT: Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. References Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink." Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme. However, data evaluating the interaction are not available.
MANAGEMENT: Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: griseofulvin
Brand name: Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
Synonyms: Griseofulvin
Generic Name: nitisinone
Brand name: Orfadin, Nityr
Synonyms: Orfadin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Griseofulvin Ultramicrosize Tablets-Orfadin Suspension
- Griseofulvin Ultramicrosize Tablets-Orfro
- Griseofulvin Ultramicrosize Tablets-Orgaran
- Griseofulvin Ultramicrosize Tablets-Orilissa
- Griseofulvin Ultramicrosize Tablets-Oritavancin
- Griseofulvin Ultramicrosize Tablets-Oritavancin Diphosphate
- Orfadin (Nitisinone Oral Suspension)-Guaiatussin AC
- Orfadin (Nitisinone Oral Suspension)-Guaifen DAC
- Orfadin (Nitisinone Oral Suspension)-Guaifenesin AC Liquid
- Orfadin (Nitisinone Oral Suspension)-Guaifenesin and Codeine
- Orfadin (Nitisinone Oral Suspension)-Guaifenesin and Dextromethorphan Capsules and Tablets
- Orfadin (Nitisinone Oral Suspension)-Guaifenesin and Dextromethorphan Extended-Release Tablets